Listing 1 - 5 of 5 |
Sort by
|
Choose an application
The use of targeted cytotoxins to make highly selective neural lesions for both experimental and clinical purposes has already provided important animal models for diseases such as Alzheimer's, and holds great promise for research and clinical application to pain. In Molecular Neurosurgery With Targeted Toxins, pioneers in the field describe their hands-on experience with the experimental use of these toxins. The authors focus on the highly successful use of the immunotoxins, 192 IgG-saporin and ME20.4-saporin, to lesion the cholinergic basal forebrain in order to model the behavior, anatomy, physiology, and pharmacology of Alzheimer's disease in animals. Also discussed are the uses of anti-DBH-saporin immunotoxin to make remarkably selective lesions of catecholaminergic neurons, hypocretin-saporin that can produce narcoleptic animals, and other saporin conjugates, such as neuropeptide-saporin conjugates for pain research and cholera toxin B chain-saporin to produce a model of central nervous system demyelination. Overview perspectives and, in some cases, more practical details are provided that allow the reader to appreciate exactly what is involved in using these agents. Both practical and theoretical, Molecular Neurosurgery With Targeted Toxins provides readers with not only the background to understand these techniques, but also numerous real-life examples that can be readily adapted to new purposes and an ever-increasing number of new targeted toxins.
Neurotoxic agents --- Drug targeting. --- Antibody-toxin conjugates --- Therapeutic use. --- Conjugates, Antibody-toxin --- Immunoconjugates --- Immunoglobulin-toxin conjugates --- Immunotoxins --- Toxin-antibody conjugates --- Toxin-immunoglobulin conjugates --- Bioconjugates --- Immunopharmacology --- Immunotoxicology --- Toxins --- Drugs --- Site-specific drug delivery --- Targeting of drugs --- Target organs (Anatomy) --- Neuropoisons --- Neurotoxicants --- Neurotoxins --- Poisons --- Targeting --- Dosage forms --- Neurosurgery. --- Nerves --- Neurosurgery --- Surgery --- Nervous system --- Surgery.
Choose an application
This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field.
Biomedicine. --- Pharmaceutical Sciences/Technology. --- Medicine. --- Pharmaceutical technology. --- Médecine --- Techniques pharmaceutiques --- Antibody-drug conjugates. --- Antibody-toxin conjugates. --- Drugs -- Research. --- Health & Biological Sciences --- Pharmacy, Therapeutics, & Pharmacology --- Conjugates, Antibody-toxin --- Immunoconjugates --- Immunoglobulin-toxin conjugates --- Immunotoxins --- Toxin-antibody conjugates --- Toxin-immunoglobulin conjugates --- Conjugates, Antibody-drug --- Drug-antibody conjugates --- Drug immunoconjugates --- Drug-immunoglobulin conjugates --- Immunoconjugates, Drug --- Immunoglobulin-drug conjugates --- Bioconjugates --- Immunopharmacology --- Immunotoxicology --- Toxins --- Drugs --- Dosage forms --- Pharmaceutical laboratory techniques --- Pharmaceutical laboratory technology --- Technology, Pharmaceutical --- Technology
Choose an application
This volume is a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance.
Biomedicine. --- Cancer Research. --- Drug Resistance. --- Pharmacology/Toxicology. --- Medicine. --- Oncology. --- Drug interactions. --- Toxicology. --- Médecine --- Cancérologie --- Médicaments --- Toxicologie --- Interaction --- Medicine --- Health & Biological Sciences --- Oncology --- Antibody-toxin conjugates. --- Cancer --- Treatment. --- Cancer therapy --- Cancer treatment --- Conjugates, Antibody-toxin --- Immunoconjugates --- Immunoglobulin-toxin conjugates --- Immunotoxins --- Toxin-antibody conjugates --- Toxin-immunoglobulin conjugates --- Therapy --- Cancer research. --- Drug resistance. --- Pharmacology. --- Bioconjugates --- Immunopharmacology --- Immunotoxicology --- Toxins --- Chemicals --- Pharmacology --- Poisoning --- Poisons --- Interactions, Drug --- Drugs --- Tumors --- Toxicology --- Side effects --- Drug effects --- Medical pharmacology --- Medical sciences --- Chemotherapy --- Pharmacy --- Resistance to drugs --- Cancer research --- Physiological effect
Choose an application
This book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of action and off target activities. The book introduces scientists to all of the prerequisites that must be properly addressed, including identification of the right target, specific traits of target binding antibodies, proper selection of the toxic payload, internalization induced by binding, and next generation conjugation and linker technologies. These knowledge-based, revolutionary new drug principles will form the cornerstone of the future standard of care and will lead to major advances in application, as well as improved quality of life and patient survival rates. This book will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology.
Medicine. --- Cancer research. --- Antibodies. --- Pharmacology. --- Oncology. --- Pharmacotherapy. --- Biomedicine. --- Pharmacology/Toxicology. --- Cancer Research. --- Antibody-toxin conjugates. --- Conjugates, Antibody-toxin --- Immunoconjugates --- Immunoglobulin-toxin conjugates --- Immunotoxins --- Toxin-antibody conjugates --- Toxin-immunoglobulin conjugates --- Bioconjugates --- Immunopharmacology --- Immunotoxicology --- Toxins --- Toxicology. --- Monoclonal antibodies. --- Oncology . --- Tumors --- Antibodies, Monoclonal --- Monoclonal immunoglobulins --- Immunoglobulins --- Molecular cloning --- Chemicals --- Medicine --- Pharmacology --- Poisoning --- Poisons --- Toxicology --- Cancer research --- Drug therapy --- Pharmacotherapy --- Therapeutics --- Drugs --- Antibodies --- Immune globulins --- Immune serum globulin --- Blood proteins --- Globulins --- Plasma cells --- Antibody diversity --- Antigens --- Bacterial immunoglobulin-binding proteins --- Drug effects --- Medical pharmacology --- Medical sciences --- Chemotherapy --- Pharmacy --- Physiological effect
Choose an application
The concept of delivering ‘magic bullets’ to treat diseases was first proposed by Paul Erlich in the early 1900’s. The realization of this concept for the treatment of cancer occurred in the late 1990’s with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics. More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use. This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer.
Antibodies. --- Antibody-drug conjugates. --- Immunotoxins -- Therapeutic use. --- Antibody-drug conjugates --- Antibody-toxin conjugates --- Diseases --- Pharmaceutical Preparations --- Immunoconjugates --- Immunoglobulins --- Therapeutics --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Immunoproteins --- Chemicals and Drugs --- Blood Proteins --- Proteins --- Amino Acids, Peptides, and Proteins --- Immunotoxins --- Neoplasms --- Drug Therapy --- Antibodies --- Drug Combinations --- Medicine --- Health & Biological Sciences --- Oncology --- Antibody-toxin conjugates. --- Conjugates, Antibody-toxin --- Immunoglobulin-toxin conjugates --- Toxin-antibody conjugates --- Toxin-immunoglobulin conjugates --- Conjugates, Antibody-drug --- Drug-antibody conjugates --- Drug immunoconjugates --- Drug-immunoglobulin conjugates --- Immunoconjugates, Drug --- Immunoglobulin-drug conjugates --- Medicine. --- Cancer research. --- Biomedicine. --- Cancer Research. --- Biomedicine general. --- Immune globulins --- Immune serum globulin --- Blood proteins --- Globulins --- Plasma cells --- Antibody diversity --- Antigens --- Bacterial immunoglobulin-binding proteins --- Cancer research --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians --- Bioconjugates --- Immunopharmacology --- Immunotoxicology --- Toxins --- Drugs --- Dosage forms --- Oncology. --- Monoclonal antibodies. --- Antibodies, Monoclonal --- Monoclonal immunoglobulins --- Molecular cloning --- Tumors --- Health Workforce --- Biomedicine, general.
Listing 1 - 5 of 5 |
Sort by
|